Decera Clinical Education Medical Specialties Podcast

This podcast episode is part of a multimedia program discussing the impact of health disparities in anemia of chronic kidney disease (CKD) on patient outcomes. Tune in to hear Santosh Saraf, MD, and Milda Saunders, MD, MPH, highlight mitigation strategies to improve screening and management. The overview will include:  The definition of CKD and the relative prevalence in specific minority groups H...

In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis. Pres...

In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes. Presenters Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine  Tulane Heart and Vascular Institute...

In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes. Presenters Keith C. Ferdinand, MD, FACC, FAHA  Professor of Medicine  Tulane Heart and Vasc...

In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include:  Disproportionate prevalence among marginalized groups in the United States Lupus-related social determinants of health Challenges with medication adherence Strategies to reduce these disparities Presenters: Karen H. Costenbader, MD,...

This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes. Rev...

This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcom...

This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future stud...

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss the recent changes in rheumatoid arthritis treatment options, reviewing the landscape of targeted DMARDs and JAK inhibitors, including: Kinase signaling JAK inhibitor activity and signaling JAK selectivity Presenters: Stanley B. Cohen, MD Clinical Professor   Department of Internal Medicine University of Texas Sou...

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series in bDMARD-IR MTX-IR MTX naive Also included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cycling Presenters: Stanley B. Cohen, MD Clinic...

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss how to translate information on JAK inhibitors and other treatments for your patient population in the clinic, covering practical tips on using: Treat-to-target approaches Disease activity measures Shared decision-making Decision aids Translating clinical trial evidence Also included are the experts’ answers to qu...

What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH. Download the slides from this podcast at: https://bit.ly/3gpzuMj See more NASH topics at: https://bit.ly/3ezkBq6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertisin...

Hear  Brent A. Neuschwander-Tetri, MD,  explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including: Should We Screen for NASH? Role of obesity and type 2 diabetes mellitus Cardiovascular Risk in NAFLD/NASH How to Evaluate for NAFLD/NASH Biomarkers Imaging When/whom to biopsy? Management in Multidisciplinary Settings Download the slides from this...

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in: • Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2 • Assessment of therapeutic response • Assessment of long-term patient outcomes Download the slides from this podcast at: https://bit.ly/3il5rqG See more NASH topics at:  https:...

Hear  Philip N. Newsome, PhD, FRCPE, discussavailable approaches to managing NASH, including lifestyle, vitamin E, and compounds that target insulin resistance, including: Recommended Pharmacologic Therapies for NASH Pioglitazone Vitamin E Optimal Diabetes Therapies in NAFLD/NASH Weight Loss Liver Health Surgical Approaches to Weight Loss and Effect on Liver Download the slides from this podcast a...

Hear  Dr. Katherine Wagner * and * Dr. Richard Finkle discussnovel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored. Download the slides from this podcast at:  https:/...

Hear  Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as: Obeticholic acid Cenicriviroc Resmetirom Aramchol Download the slides from this podcast at: https://bit.ly/3eJYKvW See more NASH topics at:  https://bit.ly/3ezkBq6 Hosted by Simplecast, an AdsWizz company. See pcm...

Link to CME: Claim Credit - https://bit.ly/3dQPQwT . Continuous glucose monitoring (CGM) is a great tool that improves clinical outcomes for people with diabetes; these individuals are often happy to get this new technology. However, there can be some initial barriers that both people with diabetes and clinicians need to overcome. BARRIER 1 : Wearing something on the body so other people know the...